Greenwich LifeSciences, Inc. GLSI

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

are a clinical-stage biopharmaceutical company focused on our Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an

immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface

receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate

(2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. We are currently expanding Flamingo-01

Last close 16.03 2026-10-23
Market cap $235.3M 2026-06-30 share count
52-week range 7.78 - 34.10

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-1.43

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
R&D $17.2M$15.5M$7.7M$6.5M$3.6M$1.1M$2.6M—
SG&A $2.2M$2.2M$1.6M$1.6M$1.0M$806.2K$818.9K—
Total operating expenses $19.4M$17.6M$9.3M$8.0M$4.6M$1.9M$3.4M—
Operating income -$19.4M-$17.6M-$9.3M-$8.0M-$4.6M-$1.9M-$3.4M—
Net income -$19.4M-$17.4M-$8.9M-$7.8M-$4.6M-$1.9M-$3.4M—
EPS, basic -1.43-1.34-0.69-0.61-0.35———
EPS, diluted -1.43-1.34-0.69-0.61-0.35-0.20-1.52—
Shares, diluted (wtd. avg.) 13.5M13.0M12.8M12.9M————

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents $6.2M$4.1M$7.0M$13.5M$27.2M$28.7M$6.8K—
Total current assets $6.2M$4.1M———$28.7M$6.8K—
Other intangibles —$1.8K$5.4K$9.0K$12.6K$16.2K$19.8K—
Total assets $6.2M$4.1M$7.0M$13.5M$27.2M$28.7M$26.7K—
Accounts payable $4.9M$2.8M$256.3K$220.8K$220.8K$711.0K$730.3K—
Total current liabilities $5.8M$3.2M$294.4K$262.9K$385.2K$1.0M$1.4M—
Total liabilities $2.5M$3.2M$294.4K$262.9K$385.2K$1.0M$1.4M—
Retained earnings -$87.1M-$67.8M-$50.4M-$41.5M-$33.6M-$29.1M-$27.2M—
Total equity $353.2K$908.6K$6.7M$13.2M$26.8M$27.6M-$1.4M-$10.1M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Operating cash flow -$9.9M-$7.3M-$6.5M-$6.2M-$4.3M-$1.2M-$293.3K—
Stock-based compensation $6.8M$7.3M$2.4M$1.7M$660.6K$678.0K$194.9K—
Financing cash flow $12.0M$4.4M—-$7.5M$2.8M$29.8M$215.0K—
Buybacks ———$7.5M————

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-026651.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -20M -15M -10M -5M 0 Net income, FY2019: -3.4M Net income, FY2020: -1.9M Net income, FY2021: -4.6M Net income, FY2022: -7.8M Net income, FY2023: -8.9M Net income, FY2024: -17.4M Net income, FY2025: -19.4M FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — — — — — — — —
Gross profit — — — — — — — —
Net income — -$3.4M -$1.9M -$4.6M -$7.8M -$8.9M -$17.4M -$19.4M

Recent filings and events

  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Auditor changed The company changed auditors. Sometimes routine; historically one of the more reliable warnings that something is wrong. Item 4.01
  • Annual report filed Form 10-K
  • Shareholder vote Item 5.07
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
  • Annual report filed Form 10-K
  • Auditor changed Item 4.01
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Shareholder vote Item 5.07

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%